Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ABOS 
Acumen Pharmaceuticals Inc (ABOS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: ABOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.75
1 Year Target Price $6.75
| 5 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34.39% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 122.96M USD | Price to earnings Ratio - | 1Y Target Price 6.75 |
Price to earnings Ratio - | 1Y Target Price 6.75 | ||
Volume (30-day avg) 5 | Beta 0.2 | 52 Weeks Range 0.85 - 3.36 | Updated Date 10/18/2025 |
52 Weeks Range 0.85 - 3.36 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.06% | Return on Equity (TTM) -75.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6053038 | Price to Sales(TTM) 538.78 |
Enterprise Value -6053038 | Price to Sales(TTM) 538.78 | ||
Enterprise Value to Revenue 89.67 | Enterprise Value to EBITDA -0.6 | Shares Outstanding 60573425 | Shares Floating 35610511 |
Shares Outstanding 60573425 | Shares Floating 35610511 | ||
Percent Insiders 7.03 | Percent Institutions 67.82 |
Upturn AI SWOT
Acumen Pharmaceuticals Inc
Company Overview
History and Background
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for Alzheimer's disease. Founded to target toxic amyloid-beta oligomers (Au03b2Os), it aims to address a root cause of the disease. The company has advanced its lead candidate, sabirnetug, into clinical trials.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical testing of therapeutic candidates for Alzheimer's disease.
- Amyloid-beta Oligomer (Au03b2O) Targeting: Concentrates on developing therapies that selectively target and neutralize toxic Au03b2Os.
Leadership and Structure
The leadership team includes key executives in research, development, and finance. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Sabirnetug: A monoclonal antibody designed to selectively target and neutralize toxic amyloid-beta oligomers (Au03b2Os). Currently in Phase 1 clinical trials. There is no current market share. Competitors include therapies targeting amyloid plaques such as Leqembi (Eisai and Biogen) and donanemab (Eli Lilly).
Market Dynamics
Industry Overview
The Alzheimer's disease treatment market is large and growing, driven by an aging population and increasing prevalence. The market is characterized by high unmet need and significant investment in research and development.
Positioning
Acumen is positioned as a developer of therapies specifically targeting Au03b2Os, a distinct approach compared to those targeting amyloid plaques. This positions them as potentially offering a more targeted and effective treatment option.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of dollars. Acumen's focus on Au03b2Os allows it to potentially capture a significant share if its therapies prove effective.
Upturn SWOT Analysis
Strengths
- Novel Au03b2O targeting approach
- Lead candidate in clinical trials
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Single clinical-stage asset
- High development risk
- Limited financial resources compared to larger pharmaceutical companies
- No current revenue stream
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new Au03b2O-targeting therapies
- Breakthrough Therapy designation
Threats
- Clinical trial failures
- Competition from other Alzheimer's therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ESALY
Competitive Landscape
Acumen faces significant competition from established pharmaceutical companies with larger resources. Its Au03b2O targeting approach provides a unique selling proposition, but its success depends on clinical trial outcomes.
Growth Trajectory and Initiatives
Historical Growth: Acumen's historical growth is primarily defined by its progress in research and development.
Future Projections: Future growth depends heavily on the success of sabirnetug in clinical trials and potential partnerships.
Recent Initiatives: Advancement of sabirnetug into clinical trials.
Summary
Acumen Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on a novel approach to Alzheimer's treatment. Success hinges on positive clinical trial data for sabirnetug. The company faces significant competition but the unique Au03b2O targeting strategy could provide competitive edge. Funding and partnerships will be crucial for continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available)
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acumen Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Newton, MA, United States | ||
IPO Launch date 2021-07-01 | CEO & Director Mr. Daniel J. O'Connell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://acumenpharm.com |
Full time employees 61 | Website https://acumenpharm.com | ||
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.